Literature DB >> 14532772

Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program.

Badrinath R Konety1, Sue A Joslyn.   

Abstract

PURPOSE: We examined the association of various demographic, geographic and disease related factors, and the use of aggressive therapy defined as radical cystectomy or radiation therapy for bladder cancer. We also examined the correlation between these factors and disease specific survival such aggressive therapy.
MATERIALS AND METHODS: Data from the Surveillance, Epidemiology and End Results (SEER) program public use files from 1992 to 1999 were used to analyze the demographic and disease related variables of patient age, sex, race, reporting SEER site/geographic region, disease stage, number of lymph nodes examined and number of positive lymph nodes. Cox proportional hazards model analysis was used to test for associations with disease specific survival and logistic regression was used to test the predictors of aggressive therapy.
RESULTS: In multivariate models age, SEER site and disease stage were predictors of radical cystectomy while race, age, sex, SEER site and disease stage were significant factors predicting likelihood of radiation therapy. Disease stage and number of nodes examined were significantly associated with survival after radical cystectomy, while age, sex, SEER site and stage significantly affected survival after radiation therapy.
CONCLUSIONS: Demographic, geographic and disease related characteristics of the patient population can significantly affect treatment choice in patients with bladder cancer. Disease specific survival after radical cystectomy appears to be influenced only by disease related factors (stage and extent of lymphadenectomy) compared to radiation therapy, where survival is influenced by nondisease related factors such as age, sex and SEER site. A significant number of patients who are older or live in certain geographic areas who are being denied aggressive therapy for bladder cancer would benefit from such therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14532772     DOI: 10.1097/01.ju.0000091620.86778.2e

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

Review 1.  Challenging treatment decision-making in older urologic cancer patients.

Authors:  Guillaume Ploussard; Gilles Albrand; François Rozet; Hervé Lang; Elena Paillaud; Pierre Mongiat-Artus
Journal:  World J Urol       Date:  2013-08-30       Impact factor: 4.226

2.  Is there a gender effect in bladder cancer? A population-based study of practice and outcomes.

Authors:  Francis Michael Patafio; D Robert Siemens; Xuejiao Wei; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

3.  Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Authors:  Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

4.  Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder.

Authors:  Ken-ichi Harada; Iori Sakai; Toshifumi Kurahashi; Mototsugu Muramaki; Kazuki Yamanaka; Isao Hara; Hiroshi Eto; Hideaki Miyake
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 5.  Neoadjuvant chemotherapy for bladder cancer.

Authors:  Peter C Black; Gordon A Brown; H Barton Grossman; Colin P Dinney
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Variations in reconstruction after radical cystectomy.

Authors:  John L Gore; Christopher S Saigal; Jan M Hanley; Matthias Schonlau; Mark S Litwin
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

7.  Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries.

Authors:  Jeffrey C Bassett; JoAnn Alvarez; Tatsuki Koyama; Matthew Resnick; Chaochen You; Shenghua Ni; David F Penson; Daniel A Barocas
Journal:  J Gen Intern Med       Date:  2014-12-02       Impact factor: 5.128

8.  Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.

Authors:  John L Gore; Julie Lai; Claude M Setodji; Mark S Litwin; Christopher S Saigal
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

Review 9.  Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction.

Authors:  John A Taylor; George A Kuchel
Journal:  Nat Clin Pract Urol       Date:  2009-03

10.  Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation.

Authors:  Joshua A Cohn; Benjamin Vekhter; Christopher Lyttle; Gary D Steinberg; Michael C Large
Journal:  Cancer       Date:  2013-11-13       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.